NCT02917993 2026-02-09An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerIncyte CorporationPhase 1/2 Completed59 enrolled
NCT02803203 2023-09-22Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersMemorial Sloan Kettering Cancer CenterPhase 1/2 Completed49 enrolled 10 charts